The pharmaceutical giant is expected to garner $8.9 billion in sales and $2.46 in adjusted earnings per share, per the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Eli Lilly (NYSE:LLY) continues its unabated upward journey. Not only has it more than doubled its price in the past year, but it’s up by 33.6% in the first quarter of 2024 (Q1 2024) as well.

Eli Lilly Aims To Close Supply-Demand Gap For Zepbound/Mounjaro As It Acquires Manufacturing Facility From Nexus Pharma Eli Lilly expands its global manufacturing network with FDA-approved ...

Eli Lilly shares have climbed in the triple digits over the past year, and earnings have soared too. The company sells two of the world’s most sought-after products right now: weight-loss drugs.

Eli Lilly's weight loss-related drug Zepbound could potentially be used to reduce the severity of sleep apnea in adults with obesity, according to a recent study. Results of a phase three ...

Eli Lilly’s weight loss drug Zepbound has been shown to “significantly reduce” obstructive sleep apnea (OSA) in adults with obesity, the company said Wednesday. Injections of tirzepatide ...

The diabetes and weight loss drug tirzepatide appears to help people with obesity who also have sleep apnea, according to preliminary findings from drugmaker Eli Lilly. The results, while ...

April 22 (Reuters) - Eli Lilly said on Monday that it will acquire a manufacturing facility from Nexus Pharmaceuticals to produce injectable medicines. Lilly expects production at the facility ...